Name: PROTAC ERRα Degrader-3
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

≥98%

Solubility

Soluble in DMSO

Storage

Store at -20°C

IUPACName

(2S,4R)-1-[(2S)-2-[5-[[(E)-3-[4-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-3-methoxyphenyl]-2-cyanoprop-2-enoyl]amino]pentanoylamino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

Synonyms

N-(5-{[(2E)-3-(4-{[2,4-Bis(trifluoromethyl)benzyl]oxy}-3-methoxyphenyl)-2-cyano-2-propenoyl]amino}pentanoyl)-3-methyl-L-valyl-(4R)-4-hydroxy-N-[4-(4-methyl-1,3-thiazol-5-yl)benzyl]-L-prolinamide; L-Prolinamide, N-[5-[[(2E)-3-[4-[[2,4-bis(trifluoromethyl)phenyl]methoxy]-3-methoxyphenyl]-2-cyano-1-oxo-2-propen-1-yl]amino]-1-oxopentyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-

Boiling Point

1058.6±65.0°C at 760 mmHg

Density

1.326±0.06 g/cm3

InChI Key

POTUUCUOBIVSIX-BDUCEWPUSA-N

InChI

InChI=1S/C47H50F6N6O7S/c1-27-40(67-26-57-27)30-12-9-28(10-13-30)23-56-43(63)36-21-34(60)24-59(36)44(64)41(45(2,3)4)58-39(61)8-6-7-17-55-42(62)32(22-54)18-29-11-16-37(38(19-29)65-5)66-25-31-14-15-33(46(48,49)50)20-35(31)47(51,52)53/h9-16,18-20,26,34,36,41,60H,6-8,17,21,23-25H2,1-5H3,(H,55,62)(H,56,63)(H,58,61)/b32-18+/t34-,36+,41-/m1/s1

SMILES

CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)CCCCNC(=O)C(=CC4=CC(=C(C=C4)OCC5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)OC)C#N)O

Mechanism

Target: Targets estrogen-related receptor alpha (ERRα) for experimental targeted protein degradation studies.

Binding Site: Binds the ERRα ligand-binding domain and recruited E3 ligase ligand site to support productive ternary complex formation.

Mechanism of Action: PROTAC ERRα Degrader-3 is designed for use in PROTAC or targeted protein degradation experiments directed toward estrogen-related receptor alpha (ERRα). The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

Applications

• PROTAC-Mediated ERRα Degradation: This product serves as a powerful tool for selectively degrading Estrogen-Related Receptor alpha (ERRα) in cellular models. By facilitating targeted protein degradation, it enables researchers to dissect ERRα's functional roles in cellular metabolism and energy homeostasis, providing insights into its broader biological implications.

• Targeted Degradation in Cancer Research: PROTAC ERRα Degrader-3 is instrumental in exploring the potential of ERRα as a therapeutic target in oncology. Its ability to specifically degrade ERRα allows for the investigation of its involvement in tumorigenesis and cancer cell proliferation, aiding in the development of novel anticancer strategies.

• Functional Proteomics via PROTACs: Utilizing PROTAC ERRα Degrader-3, researchers can perform detailed studies on the proteome dynamics associated with ERRα degradation. This approach aids in identifying downstream effectors and signaling pathways influenced by ERRα, thus contributing to a comprehensive understanding of its regulatory networks.

• Metabolic Pathway Analysis: By employing PROTAC ERRα Degrader-3, scientists can investigate the metabolic pathways regulated by ERRα. This targeted degradation strategy is crucial for elucidating ERRα's role in metabolic disorders, offering a pathway to discover new therapeutic targets for metabolic diseases.

1. Identification of new small-molecule inducers of estrogen-related receptor α (ERRα) degradation.

Peng, L., Zhang, Z., Lei, C., Li, S., Zhang, Z., Ren, X., Chang, Y., Zhang, Y., Xu, Y. and Ding, K., 2019. ACS medicinal chemistry letters, 10(5), pp.767-772.

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

does PROTAC ERRα Degrader-3 stable in room temperature?

Yes, PROTAC ERRα Degrader-3 is stable at room temperature. It is stable at room temperature and in dry conditions. It is also stable in the presence of light and heat.

21/11/2018

can PROTAC ERRα Degrader-3 be used in vitro?

Yes, PROTAC ERRα Degrader-3 can be used in vitro. It has been shown to be effective in inhibiting the growth of cancer cells in cell culture. PROTAC ERRα Degrader-3 has also been shown to be effective in killing cancer cells in animal models.

9/10/2022

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂